Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
ICICI Bank urges SC to consider Jaiprakash Associates, Jaypee Intratech as separate entities

21h livemint
New Delhi: ICICI Bank, the lead financial creditor for Jaiprakash Associates Ltd (JAL), on Tuesday urged the Supreme Court to consider JAL and its subsidiary Jaypee Intratech Ltd (JIL) as two separate entities in the ongoing legal battle with homebuyers and creditor banks.
532532 ICICIBANK 500116 JIPKY 532174 IBN IDBI JPASSOCIAT

0
IDBI Bank to seek govt nod for LIC investment

2018-07-17 moneycontrol
The public sector lender, IDBI Bank, will soon seek an approval from the government for the proposed investment by Life Insurance Corporation of India (LIC). The latter, which holds 7.98 percent stake in the bank at present will buy additional 43.02 percent in former once it gets the approval from the Cabinet.
500116 IDBI

0
IDBI Bank Limited - Updates

2018-07-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500116 IDBI

0
IDBI Bank stock climbs 6% after reports of LIC planning open offer after stake buy

2018-07-17 moneycontrol
IDBI Bank share price jumped more than 6 percent intraday Tuesday after CNBC-TV18 reported quoting agencies that insurance behemoth LIC may go for an open offer for the bank after buying 51 percent stake in it.
500116 IDBI

0
IDBI board may okay pref share allotment to LIC soon

2018-07-17 freepressjournal.in
New Delhi : IDBI Bank will soon convene the board meeting to approve allotment of preference shares to LIC, enabling the insurance behemoth to acquire 51 per cent stake in the bank.
500116 IDBI

0
News In Numbers: LIC holds more than 10% stake in 6 public sector banks

2018-07-17 livemint
What is it? China’s growth in second quarter of 2018, compared to same period last year.
532179 500116 CRPKY IDBI CORPBANK

0
Jaiprakash Associates lists proposals before SC to settle disputes

2018-07-16 livemint
New Delhi: Jaiprakash Associates Ltd (JAL) on Monday told the Supreme Court that it is ready to deposit postdated cheques for ₹600 crore with the court’s registry and sell its cement plant at Rewa, Madhya Pradesh in order to settle its ongoing legal battle with homebuyers and creditors.
532532 533207 500116 JPINFRATEC JIPKY IDBI JPASSOCIAT

0
Rupee consolidates, but is likely to extend its fall

2018-07-16 thehindubusinessline
The Indian rupee has been stuck in a sideways range between 68.3 and 69 over the last couple of weeks. Within this range, the rupee moved to a high of 68.32 on Friday, but failed to retain strength.
500116 IDBI

0
Ashok Leyland, ICICI Lombard results

2018-07-16 thehindubusinessline
Nearly two dozen companies, including 8K Miles Software Services, Ashok Leyland, Atishay, Crisil, Federal Bank, Goa Carbon, Hindustan Media Ventures, ICICI Lombard General Insurance, Integrated Capital, Jindal Stainless, Indian Metals & Ferro Alloys, Muthoot Capital Services, Nucleus Software Exports, Rallis India, Sintex Industries, Tata Sponge Iron and Zee Entertainment Enterprises will declare their April-June quarter results on Tuesday.
RALLIS GOACARBON 500469 IDBI 531209 MUTHTFN FEDA TATASPONGE FEDS 500355 JSL 500477 ZEEL FEDERALBNK 509567 ASHOKLEY 513010 500116 IBN 532508 FDBAY FERROALL AKLD 533217 511766 ICICIBANK ZEEEY 532174 SINTEX 502742 505537 500141 AKLS NUCLEUS HMVL

0
5Paisa board meet for results, rights issue

2018-07-16 thehindubusinessline
The board of 5Paisa Capital will meet on Tuesday to consider the unaudited financial results for the quarter ended June 30, and a proposal to raise capital through a rights issue. Shareholders will be keen to know the amount it plans to raise, the price, and the entitlement ratio of the issue. Recently, the board approved an increase in the FPl investment limit to the sectoral cap/statutory ceiling of 100 per cent and NRIs’ limit to 24 per cent.
ICICIBANK 500116 532174 IBN IDBI

0
MM Forgings to turn ex-bonus on Wednesday

2018-07-16 thehindubusinessline
Shares of MM Forgings will turn ex-bonus on Wednesday. The company is rewarding its shareholders with a 1:1 bonus issue. Shareholders whose name appear on the company's record book as on July 19 are eligible to receive the bonus shares. That means, investors who wish to receive the bonus shares, need to own MM Forgings shares by Tuesday. Earlier, in 2008 too, MM Forgings had rewarded its shareholders with a 1:1 bonus issue.
ICICIBANK 500116 532174 IBN IDBI

0
Minda Industries Limited

2018-07-16 thehindubusinessline
Minda Industries, the flagship company of UNO MINDA Group, has entered into another joint venture agreement with Kasei Group, Japan. Kasei Minda Mould Private Limited will be incorporated with MIL holding 49.9 per cent and Kasei group 50.1 per cent of the equity, the company said in a statement to the exchanges. The JV company is proposed to be set up in Bawal, Haryana, for manufacturing moulds for alloy wheel.
ICICIBANK 500116 532174 IBN IDBI MINDAIND 532539

0
Compuage Infocom Limited

2018-07-16 thehindubusinessline
Compuage Infocom has informed the exchanges that it has been appointed as an exclusive national distributor of CBC Corporation of Japan for the distribution of CCTV surveillance products. Shares of Compuage Infocom tumbled 5.6 per cent at ₹30.10 on the NSE.
ICICIBANK 500116 532174 IBN IDBI COMPUAGE 532456

0
Broker's call: Karnataka Bank (Buy)

2018-07-16 thehindubusinessline
In Q1FY19, Karnataka Bank’s (KBL) NII has improved by 10.4 per cent y-o-y to ₹468.6 crore but down 13.46 per cent q-o-q. It’s net profit for the quarter, which has come at ₹163.2 crore against ₹133.8 crore y-o-y, which is up by 22 per cent. NIMs for the quarter has improved by 3 bps y-o-y to 3 per cent. GNPA for Q1FY19 stood at 4.72 per cent against 4.92 per cent q-o-q, which has declined by 20 bps.
532652 500116 IDBI KTKBANK

0
IDBI Bank board may soon clear preferential share allotment to LIC

2018-07-16 livemint
New Delhi: IDBI Bank will soon convene the board meeting to approve allotment of preference shares to LIC, enabling the insurance behemoth to acquire a 51% stake in the bank.
500116 IDBI

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...